Literature DB >> 22021428

GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer.

Yu Wang1, Xin He, Joanne Ngeow, Charis Eng.   

Abstract

The tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) plays important roles in tumor development and progression. Among many functions, PTEN negatively regulates the AKT anti-apoptotic signaling pathway, while nuclear PTEN affects the cell cycle by repressing the mitogen-activated protein kinase pathway. However, the regulation of PTEN expression is still not well understood. We previously reported that androgen receptor (AR) activates PTEN transcription in breast cancer cells. Here, we found that the transcription factor GATA2 (GATA binding protein 2) is overexpressed in non-cultured human breast carcinomas and is negatively correlated with PTEN expression. We then showed GATA2 promotes breast cancer cell growth and stimulates AKT phosphorylation by inhibiting PTEN transcription. We mapped a GATA2-binding site in the PTEN promoter, whereby GATA2 not only blocks AR-induced PTEN expression by preventing AR nuclear translocation, but also directly represses PTEN transcription independent of AR. Most importantly, for the first time, we have discovered a novel reverse regulation within the traditional PTEN/AKT signaling pathway, whereby AKT induces GATA2 with consequent decreased PTEN transcription, likely germane in tumor invasion and metastases but not initiation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021428     DOI: 10.1093/hmg/ddr491

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  29 in total

1.  Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.

Authors:  Deli Liu; Michael A Augello; Ivana Grbesa; Davide Prandi; Yang Liu; Jonathan E Shoag; R Jeffrey Karnes; Bruce J Trock; Eric A Klein; Robert B Den; Francesca Demichelis; Elai Davicioni; Andrea Sboner; Christopher E Barbieri
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

2.  Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial.

Authors:  Lee Shaashua; Maytal Shabat-Simon; Rita Haldar; Pini Matzner; Oded Zmora; Moshe Shabtai; Eran Sharon; Tanir Allweis; Iris Barshack; Lucile Hayman; Jesusa Arevalo; Jeffrey Ma; Maya Horowitz; Steven Cole; Shamgar Ben-Eliyahu
Journal:  Clin Cancer Res       Date:  2017-05-10       Impact factor: 12.531

3.  Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma.

Authors:  Inga Peters; Natalia Dubrowinskaja; Hossein Tezval; Mario W Kramer; Christoph A von Klot; Jörg Hennenlotter; Arnulf Stenzl; Ralph Scherer; Markus A Kuczyk; Jürgen Serth
Journal:  Target Oncol       Date:  2014-09-19       Impact factor: 4.493

Review 4.  PTEN-opathies: from biological insights to evidence-based precision medicine.

Authors:  Lamis Yehia; Joanne Ngeow; Charis Eng
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

5.  GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway.

Authors:  Zhongyong Wang; Hui Yuan; Chao Sun; Liang Xu; Yanming Chen; Qing Zhu; Haifeng Zhao; Qiang Huang; Jun Dong; Qing Lan
Journal:  Med Oncol       Date:  2015-02-24       Impact factor: 3.064

6.  Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer.

Authors:  Lei Chen; Beihai Jiang; Zaozao Wang; Maoxing Liu; Yiyuan Ma; Hong Yang; Jiadi Xing; Chenghai Zhang; Zhendan Yao; Nan Zhang; Ming Cui; Xiangqian Su
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

7.  An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Authors:  Alison Y Zhang; Karen Chiam; Ygal Haupt; Stephen Fox; Simone Birch; Wayne Tilley; Lisa M Butler; Karen Knudsen; Clay Comstock; Krishan Rasiah; Judith Grogan; Kate L Mahon; Tina Bianco-Miotto; Carmela Ricciardelli; Maret Böhm; Susan Henshall; Warick Delprado; Phillip Stricker; Lisa G Horvath; James G Kench
Journal:  Int J Cancer       Date:  2018-12-04       Impact factor: 7.396

Review 8.  PTEN modulators: a patent review.

Authors:  Chandra S Boosani; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2013-02-05       Impact factor: 6.674

9.  The Role of Androgen Receptor in Breast Cancer.

Authors:  Domenico Iacopetta; Yassine Rechoum; Suzanne Aw Fuqua
Journal:  Drug Discov Today Dis Mech       Date:  2012

Review 10.  PTEN in Hereditary and Sporadic Cancer.

Authors:  Joanne Ngeow; Charis Eng
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.